AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment.
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab) - read this article along with other careers information, tips and advice on BioSpace
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start